CASI CASI Pharmaceuticals Inc.

2.95
-0.08  -3%
Previous Close 3.03
Open 3.01
Price To Book 3.55
Market Cap 284,222,101
Shares 96,346,475
Volume 126,792
Short Ratio
Av. Daily Volume 114,393
Stock charts supplied by TradingView

NewsSee all news

  1. CASI Pharmaceuticals Announces China NMPA Approval Of CNCT19 (CD19 CAR-T) Clinical Trial Applications

    ROCKVILLE, Md. and BEIJING, Dec. 3, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical

  2. CASI Pharmaceuticals Announces Third Quarter 2019 Financial Results

    ROCKVILLE, Md. and BEIJING, Nov. 12, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a U.S. biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products,

  3. CASI Pharmaceuticals Enters Exclusive China Distribution License Agreement For Octreotide Long Acting Injectable (LAI) Microsphere For Neuroendocrine Cancers And Acromegaly

    ROCKVILLE, Md. and BEIJING, Nov. 7, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical

  4. CASI Pharmaceuticals Announces The Promotion Of Larry Zhang To President

    ROCKVILLE, Md., Sept. 19, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a U.S. biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products, announces the

  5. China NMPA Accepts Clinical Trial Application For CASI's CD19 CAR-T-Product

    ROCKVILLE, Md., Sept. 16, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a U.S. biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products, announces that

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 completed. Will not further development.
ENMD-2076
Cancer - Advanced/Metastatic Soft Tissue Sarcoma
Phase 2 initiated July 2012. Noted April 14, 2017 that further patient enrollment has been stopped.
ENMD-2076
Cancer - triple-negative breast cancer
Phase 1 trial to commence in 2020.
CID-103
Multiple myeloma

Latest News

  1. CASI Pharmaceuticals Announces China NMPA Approval Of CNCT19 (CD19 CAR-T) Clinical Trial Applications

    ROCKVILLE, Md. and BEIJING, Dec. 3, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical

  2. CASI Pharmaceuticals Announces Third Quarter 2019 Financial Results

    ROCKVILLE, Md. and BEIJING, Nov. 12, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a U.S. biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products,

  3. CASI Pharmaceuticals Enters Exclusive China Distribution License Agreement For Octreotide Long Acting Injectable (LAI) Microsphere For Neuroendocrine Cancers And Acromegaly

    ROCKVILLE, Md. and BEIJING, Nov. 7, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical

  4. CASI Pharmaceuticals Announces The Promotion Of Larry Zhang To President

    ROCKVILLE, Md., Sept. 19, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a U.S. biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products, announces the

  5. China NMPA Accepts Clinical Trial Application For CASI's CD19 CAR-T-Product

    ROCKVILLE, Md., Sept. 16, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a U.S. biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products, announces that

  6. CASI Pharmaceuticals, Inc. to Host Key Opinion Leader Symposium on September 10, 2019 in New York City

    ROCKVILLE, Md., Sept. 5, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a U.S. biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products in China, U.S.,

  7. CASI Pharmaceuticals, Inc. To Present At The 2019 H.C. Wainwright 21st Annual Global Investment Conference

    ROCKVILLE, Md., Sept. 3, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a U.S. biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products in China, U.S.,